Mankind Pharma's September-quarter performance was supported by 15.9% growth in domestic pharmaceutical revenue, excluding consumer healthcare, to Rs 3,428 crore. However, performance in consumer healthcare will remain key monitorable.
Mankind Pharma's September-quarter performance was supported by 15.9% growth in domestic pharmaceutical revenue, excluding consumer healthcare, to Rs 3,428 crore. However, performance in consumer healthcare will remain key monitorable.
<iframe src="https://hindustansphere.com/embed/cluster/4d7263f5fc8424e28943cb2895a56216b69d2292" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Mankind Pharma Shares Jump Nearly 8% After Q2 Profit Rises 39%"></iframe>
